Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Metformin, a common type 2 diabetes drug, is being investigated for anti-cancer properties.
• Epidemiological studies suggest reduced cancer incidence and mortality in metformin-treated patients.
• The precise molecular mechanisms of metformin's anti-cancer effects remain unclear.

Purpose of the Study:

• To review the evidence for metformin's anti-lung cancer effects.
• To explore metformin's molecular targets and mechanisms of action in lung cancer.
• To evaluate metformin's synergistic potential with existing cancer treatments.

Main Methods:

• Review of preclinical and clinical studies on metformin in lung cancer.
• Analysis of molecular targets such as AMPK, PP2A, IRF-1/YAP, and HGF.
• Examination of proposed mechanisms including apoptosis and autophagy.

Main Results:

• Metformin influences key cellular pathways relevant to lung cancer.
• Evidence suggests potential synergistic effects with TKIs, platinum agents, and immunotherapeutics.
• Limitations and inconsistencies in current literature, particularly epidemiological studies, are identified.

Conclusions:

• Metformin exhibits promising anti-lung cancer activity through various molecular mechanisms.
• Combination therapies involving metformin may enhance treatment efficacy.
• Further research is crucial to elucidate mechanisms and optimize clinical application.